

Bhaskar Dasgupta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5040232/publications.pdf>

Version: 2024-02-01

133
papers

9,023
citations

71097

41
h-index

43886

91
g-index

138
all docs

138
docs citations

138
times ranked

5086
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: “Correspondence on “Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia” by Evangelatos et al. Annals of the Rheumatic Diseases, 2023, 82, e43-e43.	0.9	3
2	Response to: “Halo Score™: missing large vessel giant cell arteritis” do we need a modified “Halo Score?” by Chattopadhyay and Ghosh. Annals of the Rheumatic Diseases, 2022, 81, e119-e119.	0.9	4
3	Response to: “Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care” by Molina Collada et al. Annals of the Rheumatic Diseases, 2022, 81, e176-e176.	0.9	3
4	Response to: “Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues” by Ghajari and Sabour. Annals of the Rheumatic Diseases, 2022, 81, e106-e106.	0.9	2
5	Long-Term Efficacy and Safety of Leflunomide in Large-Vessel Giant Cell Arteritis. Journal of Clinical Rheumatology, 2022, 28, e297-e300.	0.9	9
6	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology, 2022, 61, 2915-2922.	1.9	24
7	Comment on: Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist. Rheumatology, 2022, , .	1.9	1
8	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 653-661.	0.9	49
9	Role of the halo sign in the assessment of giant cell arteritis: a systematic review and meta-analysis. Rheumatology Advances in Practice, 2021, 5, rkab059.	0.7	15
10	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet, The, 2021, 397, 305-317.	13.7	145
11	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatology, The, 2021, 3, e328-e336.	3.9	52
12	Current and innovative therapeutic strategies for the treatment of giant cell arteritis. Expert Opinion on Orphan Drugs, 2021, 9, 161-173.	0.8	4
13	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. Rheumatology, 2021, 60, 4361-4366.	1.9	15
14	Excellent Response to Leflunomide in a Case of Large-Vessel Giant Cell Arteritis Demonstrated Simultaneously by Clinical, Laboratory, Ultrasound, and Positron Emission Tomography/Computed Tomography Parameters. Journal of Clinical Rheumatology, 2021, 27, e254-e255.	0.9	1
15	Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. Lancet Rheumatology, The, 2021, 3, e886-e895.	3.9	15
16	Comment on: Diagnostic accuracy of ultrasound for detecting large-vessel giant cell arteritis using FDG PET/CT as the reference. Rheumatology, 2021, 60, e66-e66.	1.9	0
17	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 19-30.	0.9	667
18	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. Rheumatology, 2020, 59, 2299-2307.	1.9	21

#	ARTICLE	IF	CITATIONS
19	Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 393-399.	0.9	77
20	The role of vascular ultrasound in managing giant cell arteritis in ophthalmology. <i>Survey of Ophthalmology</i> , 2020, 65, 218-226.	4.0	5
21	Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: reply. <i>Rheumatology</i> , 2020, 59, e163-e164.	1.9	8
22	Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. <i>RMD Open</i> , 2020, 6, e001297.	3.8	29
23	Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. <i>RMD Open</i> , 2020, 6, e001417.	3.8	24
24	Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3717-3726.	1.9	26
25	A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. <i>Rheumatology and Therapy</i> , 2020, 7, 793-810.	2.3	30
26	Halo score (temporal artery, its branches and axillary artery) as a diagnostic, prognostic and disease monitoring tool for Giant Cell Arteritis (GCA). <i>BMC Rheumatology</i> , 2020, 4, 35.	1.6	13
27	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	1.9	56
28	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	1.9	128
29	Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 171-181.	0.4	13
30	Polymyalgia rheumatica and large vessel vasculitis: a case report. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa049.	0.7	0
31	Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1900-1904.	1.9	6
32	Binocular sight loss: uncommon, yet a devastating complication of GCA. <i>Rheumatology Advances in Practice</i> , 2019, 3, .	0.7	1
33	Update on the role of ultrasound in GCA/LVV and current training options in the UK. <i>Rheumatology</i> , 2019, 58, .	1.9	0
34	“Slope sign”: a feature of large vessel vasculitis?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1738-1738.	0.9	16
35	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.9	34
36	Identification of an activated neutrophil phenotype in polymyalgia rheumatica during steroid treatment: a potential involvement of immune cell cross-talk. <i>Clinical Science</i> , 2019, 133, 839-851.	4.3	6

#	ARTICLE	IF	CITATIONS
37	Glucocorticoid Dosages and Acuteâ€Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis and Rheumatology, 2019, 71, 1329-1338.	5.6	74
38	Response to: â€Correspondence to â€Slope signâ€™: a feature of large vessel vasculitis?â€™ by Milchert et al. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216690.	0.9	1
39	THU0286â€...MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2
40	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open, 2019, 5, e001020.	3.8	56
41	Giant cell arteritis: new concepts, treatments and the unmet need that remains. Rheumatology, 2019, 58, 1123-1125.	1.9	17
42	A probability score to aid the diagnosis of suspected giant cell arteritis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 104-108.	0.8	12
43	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Annals of the Rheumatic Diseases, 2018, 77, 636-643.	0.9	753
44	Current and emerging therapies in large-vessel vasculitis. Rheumatology, 2018, 57, 1513-1524.	1.9	18
45	A 26â€week feasibility study comparing the efficacy and safety of modifiedâ€release prednisone with immediateâ€release prednisolone in newly diagnosed cases of giant cell arteritis. International Journal of Rheumatic Diseases, 2018, 21, 285-291.	1.9	13
46	91.â€fA journey between the ologists: is it lupus?. Rheumatology Advances in Practice, 2018, 2, .	0.7	0
47	Prevention of glucocorticoid morbidity in giant cell arteritis. Rheumatology, 2018, 57, ii11-ii21.	1.9	34
48	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. Journal of Rheumatology, 2018, 45, 1289-1295.	2.0	49
49	Profile of tocilizumab and its potential in the treatment of giant cell arteritis. Eye and Brain, 2018, Volume 10, 1-11.	2.5	9
50	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. RMD Open, 2018, 4, e000598.	3.8	155
51	Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary SjÃ¶grenâ€™s syndrome: examination of data from the UK Primary SjÃ¶grenâ€™s Syndrome Registry. Swiss Medical Weekly, 2018, 148, w14588.	1.6	7
52	The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology, 2017, 56, kew273.	1.9	138
53	Physical activity but not sedentary activity is reduced in primary SjÃ¶grenâ€™s syndrome. Rheumatology International, 2017, 37, 623-631.	3.0	16
54	Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. RMD Open, 2017, 3, e000426.	3.8	19

#	ARTICLE	IF	CITATIONS
55	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. <i>Arthritis Care and Research</i> , 2017, 69, 1714-1723.	3.4	18
56	Tocilizumab (Actemra). <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1972-1988.	3.3	193
57	Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. <i>Nature Reviews Rheumatology</i> , 2017, 13, 578-592.	8.0	161
58	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017, 377, 317-328.	27.0	974
59	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 657-664.	3.4	62
60	A case report of neurosarcoidosis successfully treated with an infliximab biosimilar after a relapse while on dual therapy. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 356-357.	0.8	2
61	Characterising those with incident polymyalgia rheumatica in primary care: results from the PMR Cohort Study. <i>Arthritis Research and Therapy</i> , 2016, 18, 200.	3.5	20
62	009â€fUltrasound Compared with Biopsy in the Diagnosis of Suspected Giant Cell Arteritis. <i>Rheumatology</i> , 2016, 55, i37-i37.	1.9	0
63	Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis. <i>RMD Open</i> , 2016, 2, e000137.	3.8	36
64	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016, 2, e000282.	3.8	77
65	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.9	258
66	Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study. <i>Journal of Rheumatology</i> , 2016, 43, 1085-1092.	2.0	24
67	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016, 55, 1466-1476.	1.9	20
68	2015 EULARâ€ACR recommendations for polymyalgia rheumatica: the message and next steps. <i>Rheumatology</i> , 2016, 55, 955-956.	1.9	1
69	Emerging therapies in large vessel vasculitis. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 741-746.	1.9	0
70	Polymyalgia Rheumatica and Giant Cell Arteritis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2442.	7.4	346
71	Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 75-90.	1.9	38
72	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. <i>Health Technology Assessment</i> , 2016, 20, 1-238.	2.8	313

#	ARTICLE	IF	CITATIONS
73	A pragmatic approach to imaging in large vessel vasculitis. Expert Opinion on Orphan Drugs, 2015, 3, 767-775.	0.8	0
74	Balancing on the edge: implications of a UK national audit of the use of BSR-BHPR guidelines for the diagnosis and management of polymyalgia rheumatica. RMD Open, 2015, 1, e000095.	3.8	5
75	Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. RMD Open, 2015, 1, e000100.	3.8	47
76	Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. Arthritis Research and Therapy, 2015, 17, 195.	3.5	40
77	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2569-2580.	5.6	146
78	Giant Cell Arteritis: Beyond Corticosteroids. Drugs and Aging, 2015, 32, 591-599.	2.7	6
79	Polymyalgia rheumatica: strategies for efficient practice and quality assurance. Rheumatology International, 2015, 35, 1781-1789.	3.0	6
80	Improved renal function in diabetic patients with acute gout treated with anakinra. Kidney International, 2015, 88, 195-196.	5.2	17
81	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	6.2	144
82	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. Rheumatology, 2015, 55, kev373.	1.9	9
83	Imaging in Giant Cell Arteritis. Current Rheumatology Reports, 2015, 17, 52.	4.7	39
84	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1799-1807.	0.9	220
85	Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2015, 74, 1808-1817.	0.9	74
86	The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Annals of the Rheumatic Diseases, 2015, 74, 129-135.	0.9	149
87	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. PLoS ONE, 2015, 10, e0143970.	2.5	45
88	133.â€fNational Audit on Diagnosis and Management of Polymyalgia Rheumatica. Rheumatology, 2014, 53, i110-i110.	1.9	0
89	12. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gevokizumab in the treatment of giant cell arteritis. Rheumatology, 2014, 53, i7-i7.	1.9	3
90	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Annals of the Rheumatic Diseases, 2014, 73, 1607-1615.	0.9	125

#	ARTICLE	IF	CITATIONS
91	Investigational Analysis Reveals a Potential Role for Neutrophils in Giant-Cell Arteritis Disease Progression. <i>Circulation Research</i> , 2014, 114, 242-248.	4.5	68
92	P7. Gender differences in health-related quality of life in polymyalgia rheumatica. <i>Rheumatology</i> , 2014, 53, i14-i14.	1.9	1
93	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1362-1368.	0.9	87
94	Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1477-1486.	0.9	23
95	Patient and Physician Expectations of Add-On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes. <i>Arthritis Care and Research</i> , 2014, 66, 1799-1807.	3.4	13
96	Apport de l'imagerie dans la pseudo-polyarthrite rhizomélique. <i>Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.9	2
97	Contribution of imaging in Polymyalgia Rheumatica. <i>Joint Bone Spine</i> , 2013, 80, 228-229.	1.6	3
98	Imaging indications in polymyalgia rheumatica. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 39-48.	0.3	4
99	Design of the Tocilizumab in Giant Cell Arteritis Trial. <i>International Journal of Rheumatology</i> , 2013, 2013, 1-10.	1.6	96
100	Giant cell arteritis: a review. <i>Eye and Brain</i> , 2013, 5, 23.	2.5	21
101	Treatment of polymyalgia rheumatica. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 211-220.	0.8	1
102	Polymyalgia rheumatica in older adults. <i>Aging Health</i> , 2013, 9, 483-495.	0.3	4
103	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 484-492.	0.9	451
104	Diagnosis and management of polymyalgia rheumatica. <i>British Journal of General Practice</i> , 2012, 62, 275-276.	1.4	10
105	Diagnosis and assessment of polymyalgia rheumatica: a step forward. <i>Aging Health</i> , 2012, 8, 395-397.	0.3	2
106	Diagnosis and management of giant cell arteritis. <i>British Journal of General Practice</i> , 2012, 62, 329-330.	1.4	28
107	Patient-reported Outcomes in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2012, 39, 795-803.	2.0	64
108	The epidemiology of polymyalgia rheumatica in primary care: a research protocol. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 102.	1.9	18

#	ARTICLE	IF	CITATIONS
109	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis and Rheumatism, 2012, 64, 943-954.	6.7	273
110	Giant cell arteritis. BMJ: British Medical Journal, 2011, 342, d3019-d3019.	2.3	11
111	Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly. Aging Health, 2011, 7, 633-645.	0.3	19
112	Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Annals of the Rheumatic Diseases, 2011, 70, 447-453.	0.9	81
113	Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clinical Rheumatology, 2011, 30, 259-262.	2.2	47
114	Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. Rheumatology, 2011, 50, 2014-2022.	1.9	31
115	Clinical observations on the significance of raised cardiac troponin-T in patients with myositis of varying etiologies seen in rheumatology practice. Clinical Rheumatology, 2010, 29, 1107-1111.	2.2	11
116	Metabolic and Crystal Arthropathies [70-72]: 70. Single Intramuscular Depot Methylprednisolone Injection: A Convenient, Efficacious and Safe Treatment for Gouty Arthritis in an Inpatient Setting. Rheumatology, 2010, 49, i59-i61.	1.9	0
117	Concise guidance: diagnosis and management of polymyalgia rheumatica. Clinical Medicine, 2010, 10, 270-274.	1.9	15
118	Current understanding and management of giant cell arteritis and polymyalgia rheumatica. Expert Review of Clinical Immunology, 2010, 6, 913-928.	3.0	24
119	Concise guidance: diagnosis and management of giant cell arteritis. Clinical Medicine, 2010, 10, 381-386.	1.9	68
120	BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology, 2010, 49, 1594-1597.	1.9	410
121	BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology, 2010, 49, 186-190.	1.9	213
122	Reliability Exercise for the Polymyalgia Rheumatica Classification Criteria Study: The Oranjewoud Ultrasound Substudy. International Journal of Rheumatology, 2009, 2009, 1-5.	1.6	23
123	Improvement in diagnosis and management of musculoskeletal conditions with one-stop clinic-based ultrasonography. Modern Rheumatology, 2009, 19, 53-56.	1.8	31
124	Treatment and outcomes of large vessel arteritis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 325-337.	3.3	39
125	Improvement in diagnosis and management of musculoskeletal conditions with one-stop clinic-based ultrasonography. Modern Rheumatology, 2009, 19, 53-56.	1.8	20
126	Neuro-ophthalmic complications in giant cell arteritis. Current Allergy and Asthma Reports, 2008, 8, 323-330.	5.3	25

#	ARTICLE	IF	CITATIONS
127	Musculoskeletal ultrasonography: to keep pace with progress or be left behind?. International Journal of Rheumatic Diseases, 2008, 11, 109-117.	1.9	3
128	Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. Family Practice, 2008, 25, 328-333.	1.9	55
129	Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. Journal of Rheumatology, 2008, 35, 270-7.	2.0	61
130	Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis and Rheumatism, 2007, 57, 803-809.	6.7	122
131	Polymyalgia rheumatica and giant cell arteritis. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	0.5	8
132	Polymyalgia rheumatica: The mess we are now in and what we need to do about it. Arthritis and Rheumatism, 2006, 55, 518-520.	6.7	37
133	038â€fHow Common are Giant Cell Arteritis Symptoms in Patients with Polymyalgia Rheumatica? Results from an Incident Primary Care Cohort. Rheumatology, 0, , .	1.9	0